Apyx Medical Corporation has announced its financial results for the third quarter of 2026, showcasing significant growth in its Surgical Aesthetics segment. The company reported total revenue of $14.0 million, marking a 17% increase compared to the same period last year. This growth is primarily attributed to the successful commercial launch of the power liposuction handpiece for the AYON Body Contouring System.

The results were disclosed in a recent SEC filing, which highlighted the company's continued progress in the surgical aesthetics market. Apyx Medical, known for its innovative products, is positioned to capitalize on the growing demand for advanced surgical instruments.

Background

Apyx Medical Corp, incorporated in Delaware, operates in the Surgical & Medical Instruments & Apparatus sector (SIC: 3841). The company trades under the ticker symbol APYX on the Nasdaq exchange. Apyx Medical focuses on developing and marketing advanced surgical technologies, including its Renuvion and AYON systems.

What the Filing Says

The recent filing, dated November 5, 2026, reports that Apyx Medical's revenue for the third quarter was $14.0 million, up from $12.9 million in the same quarter of 2025. The company also reaffirmed its total revenue guidance for the fiscal year 2026, estimating it will be between $59.0 million and $60.0 million. The press release attached to the filing emphasized the positive reception of the newly launched power liposuction handpiece.

Impact

The reported results may significantly impact Apyx Medical's stakeholders, including investors, employees, and customers. The strong revenue growth and successful product launch suggest a solid market position, which could enhance investor confidence and attract potential customers in the surgical aesthetics field.

What's Next

Apyx Medical is set to host a conference call to discuss these results and future strategies further. The filing does not specify any additional upcoming filings or actions beyond this announcement.